Publications To Date

    nCOUNTER PUBLICATIONS

    Filter Publications

    PAGE 1 OF 12 | DISPLAYING 1 - 15 OF 173 RESULTS

    Bommareddy P.K. et. al., MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation, 10.1126/scitranslmed.aau0417 , Science, Dec 12, 2018

    Chon H.J. et. al., Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune checkpoint blockade., 10.1158/1078-0432.CCR-18-1932, Clin. Can. Res., Dec 11, 2018

    Grabosch S. et. al., Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles, https://doi.org/10.1038/s41388-018-0581-9, Oncogene, Dec 05, 2018

    Freedman J.D. et. al., An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells, 10.1158/0008-5472.CAN-18-1750, Cancer Res., Dec 01, 2018

    Christmas B.J. et. al., Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs, 10.1158/2326-6066.CIR-18-0070, Can. Immunol. Res., Dec 01, 2018

    Gomes B. et. al., Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy, 10.1158/1535-7163.MCT-17-1104, Mol. Can. Ther., Dec 01, 2018

    Fenerty K.E. et. al., Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition, 10.1186/s40425-018-0445-4, J. Immunother. Cancer, Nov 29, 2018

    Smith H.J. et. al., The antitumor effects of entinostat in ovarian cancer require adaptive immunity., 10.1002/cncr.31761, Cancer, Nov 13, 2018

    Yu J.W. et. al., Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments, 10.1371/journal.pone.0206223, PLoS ONE, Nov 02, 2018

    Du W. et. al., Sitravatinib potentiates immune checkpoint blockade in refractory cancer models, 10.1172/jci.insight.124184, JCI Insight, Nov 02, 2018

    Szekely B. et. al., Immunological differences between primary and metastatic breast cancer., doi: 10.1093/annonc/mdy399., Ann. Oncol., Nov 01, 2018

    Mukhopadhyay A. et. al., Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy, https://doi.org/10.1038/s41434-018-0044-5, Gene Therapy, Oct 15, 2018

    Cristescu R. et. al., Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy, 10.1126/science.aar3593 , Science, Oct 12, 2018

    Angelova M. et. al., Evolution of Metastases in Space and Time under Immune Selection, https://doi.org/10.1016/j.cell.2018.09.018, Cell, Oct 11, 2018

    Medler T.R. et. al., Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy, https://doi.org/10.1016/j.ccell.2018.09.003, Cancer Cell, Oct 08, 2018